Glenmark to launch new ropivacaine hydrochloride injection vials in November 2025

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Ropivacaine Hydrochloride Injection USP. This product, available in 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials, is bioequivalent and therapeutically equivalent to Naropin®2 Injection.

The company plans to commence distribution of these single-dose vials in November 2025. According to IQVIA® sales data, the market for Naropin® Injection across these concentrations achieved annual sales of approximately $20.9 million for the 12-month period ending August 2025.

Marc Kikuchi, president & business head, North America, stated that this launch significantly expands Glenmark's injectable portfolio and aims to provide quality and affordable alternatives to patients in need. Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with operations in over 80 countries.